Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In the context of australian general practice, to determine the efficacy and safety of ezetimibe 10mg/statin 40mg coadministration in patients with uncontrolled cholesterol receiving statin 40mg or more.
Condition or disease
Drug: MK0653, ezetimibe / Duration of Treatment: 6 Weeks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients who will remain on a stable statin dose of 40mg or more, for the duration of the study
Patients with coronary heart disease or diabetes mellitus whose cholesterol levels remain above the initial threshold for government subsidy after at least 3 months of treatment at a daily dose of 40mg or greater of a statin
Illnesses such as congestive heart failure nyha class iii or iv
Coronary bypass surgery or angioplasty with or without stent within 3 months of the enrolment visit
Unstable angina pectoris or unstable or severe peripheral vascular disease
Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins, ex: type i or type ii diabetes mellitus that is poorly controlled
Serum creatinine >0.18mmol/l at enrolment or active renal disease with significant proteinuria
Disorders of the haematologic, digestive (including malabsorptive disorders)
Central nervous system including cerebrovascular disease and degenerative diseases that would limit study evaluation or participation
Active acute or chronic hepatobiliary disease
Patients taking the following medication: medications known to interact with statin medication including antifungal azoles, macrolide antibiotics, telithromycin; nefazodone; protease inhibitors; amiodarone; danazol and verapamil; fibrates; cyclosporin